Question 1

What is Stryker's P/E ratio?

Accepted Answer

Stryker (SYK) P/E ratio is 35.8× as of July 22, 2026. The ratio is calculated by dividing market capitalisation by trailing twelve-month earnings (net income), using USD-normalised financials (IAS 21 exchange-rate translation for non-USD reporters).

Question 2

How is the P/E ratio calculated?

Accepted Answer

P/E = Share Price ÷ Trailing Twelve-Month (TTM) Diluted EPS, or equivalently Market Capitalisation ÷ TTM Net Income. All inputs are sourced from audited GAAP/IFRS filings and translated to USD using period-end exchange rates so the multiple is comparable across companies and currencies.

Question 3

What is the P/E ratio?

Accepted Answer

The price-to-earnings (P/E) ratio, also called the earnings multiple, measures how much investors pay per dollar of a company's trailing twelve-month (TTM) earnings. It is calculated as share price ÷ TTM diluted EPS (equivalent to market capitalisation ÷ TTM net income). A higher P/E implies the market is pricing in stronger future earnings growth or lower risk; a lower P/E can signal slower expected growth, higher risk, or potential undervaluation.

Question 4

What is a good P/E ratio for Stryker?

Accepted Answer

There is no universal "good" P/E. As a rule of thumb, the S&P 500 has historically averaged a P/E in the mid-to-high teens; mature, slow-growth businesses commonly trade in the 10–18× range, while high-growth or asset-light companies often trade at 25–50×+. What matters is the comparison to sector peers and to the company's own historical range. For Stryker specifically, the relevant sector benchmark is the current sector median of 24.2×.

Question 5

Is Stryker's P/E ratio high or low?

Accepted Answer

Stryker's P/E ratio of 35.8× is below its own 5-year average of 42.8× and above the sector median of 24.2×. That places the current reading at the 4th percentile of its 10-year history. A higher multiple usually reflects stronger expected growth, lower perceived risk, or higher returns on capital; a lower multiple reflects the opposite.

Question 6

What is Stryker's historical P/E ratio range?

Accepted Answer

In the available daily series, Stryker (SYK) P/E ratio has ranged from a low of 11.9× in 2009 to a high of 72.7× in 2021. The 5-year average is 42.8× and the 5-year median is 41.3×.

Question 7

What was Stryker's P/E ratio in 2025?

Accepted Answer

Stryker (SYK) P/E ratio at the end of 2025 was 41.4×. Annual values reflect the multiple on the last trading day of each calendar year, using the trailing twelve-month earnings figure available at that date.

Question 8

Why does Stryker's P/E ratio change over time?

Accepted Answer

Valuation multiples move with two inputs: the numerator (market capitalisation, which tracks the share price) and the denominator (earnings). Share-price changes — driven by interest rates, earnings expectations, risk appetite, and broader market sentiment — typically dominate short-term moves, while changes in the underlying fundamental drive the longer-term trend. As a result, the ratio can rise during stock-price rallies even if the business itself has not become more valuable, and fall during sell-offs even when fundamentals are improving.


2025	$134B	$3.25B	41.4×	-4.4×	Dec 31, 2025
2024	$137B	$2.99B	45.8×	+9.9×	Dec 31, 2024
2023	$114B	$3.17B	36.0×	-3.3×	Dec 31, 2023
2022	$92.5B	$2.36B	39.2×	-11.4×	Dec 31, 2022
2021	$101B	$1.99B	50.6×	-7.0×	Dec 31, 2021
2020	$92.1B	$1.6B	57.6×	+19.9×	Dec 31, 2020
2019	$78.6B	$2.08B	37.7×	+21.2×	Dec 31, 2019
2018	$58.7B	$3.55B	16.5×	-40.3×	Dec 31, 2018
2017	$58B	$1.02B	56.8×	+29.6×	Dec 31, 2017
2016	$44.9B	$1.65B	27.2×	+3.1×	Dec 31, 2016
2015	$34.8B	$1.44B	24.2×	-35.1×	Dec 31, 2015
2014	$35.7B	$602M	59.3×	+31.0×	Dec 31, 2014
2013	$28.4B	$1.01B	28.3×	+12.2×	Dec 31, 2013
2012	$20.8B	$1.3B	16.1×	+2.0×	Dec 31, 2012
2011	$18.9B	$1.35B	14.1×	-2.4×	Dec 31, 2011
2010	$20.9B	$1.27B	16.5×	-1.6×	Dec 31, 2010
2009	$20B	$1.11B	18.1×	+4.3×	Dec 31, 2009
2008	$15.8B	$1.15B	13.8×	-10.7×	Dec 31, 2008
2007	$30.7B	$1.26B	24.5×	-4.5×	Dec 31, 2007
2006	$22.5B	$776M	29.0×	+1.6×	Dec 31, 2006
2005	$18B	$657M	27.4×	-14.3×	Dec 31, 2005
2004	$19.4B	$466M	41.7×	+4.3×	Dec 31, 2004
2003	$17B	$454M	37.5×	-1.0×	Dec 31, 2003
2002	$13.3B	$346M	38.5×	—	Dec 31, 2002


Medtronic (MDT)	22.2×
McKesson (MCK)	22.2×
Illumina (ILMN)	21.7×
ResMed (RMD)	21.6×
GE HealthCare (GEHC)	21.6×
Pfizer (PFE)	21.1×
Quest Diagnostics (DGX)	21.1×
Henry Schein (HSIC)	21.0×
AptarGroup (ATR)	20.9×
IQVIA (IQV)	20.7×
Biogen (BIIB)	19.7×
Zoetis (ZTS)	18.9×
Gilead Sciences (GILD)	18.8×
Humana (HUM)	18.5×
Regeneron Pharmaceuticals (REGN)	18.2×
Bristol-Myers Squibb (BMY)	17.0×
Elevance Health (ELV)	17.0×
HCA Healthcare (HCA)	15.8×
AstraZeneca (AZN)	14.7×
DaVita (DVA)	13.3×
Incyte (INCY)	13.1×
Cigna (CI)	11.1×
Novo Nordisk (NVO)	8.6×
Solventum (SOLV)	7.9×
Universal Health Services (UHS)	7.2×

P/E Ratio for Stryker (SYK) 2002-2026

P/E Ratio daily chart for Stryker (SYK)

Historical P/E Ratio for Stryker (SYK) from 2002 to 2025

About P/E Ratio at Stryker (SYK)

Stryker P/E Ratio by Year

Stryker P/E Ratio 2025: 41.4×

Stryker P/E Ratio 2024: 45.8×

Stryker P/E Ratio 2023: 36.0×

Stryker P/E Ratio 2022: 39.2×

Stryker P/E Ratio 2021: 50.6×

Sector peers by P/E Ratio — chart

Sector peers by P/E Ratio — table

Frequently asked questions

Stryker (SYK) Key Financials